# STARTRK-1 (NCT02097810)

> Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

No report yet. It can be ordered.

- Drugs tested: entrectinib
- Indication: NTRK/ROS1/ALK-positive locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02097810
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Locally Advanced Solid Tumors; Metastatic Solid Tumors
- Interventions: Entrectinib
- Enrollment: 84
- Primary outcome: Dose-Limiting Toxicity (DLT)
- Primary outcome: Maximum Tolerated Dose (MTD)
- Primary outcome: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Overall Response Rate (ORR) in Dose Expansion

## Indexed commentary on STARTRK-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 18 posts on X
- 2 YouTube videos
- 2 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=startrk-1-nct02097810

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02097810", "email": "<work email>"}; the inbox owner confirms by the emailed link.